Obinutuzumab Maintenance in Follicular Lymphoma Is Associated With Better Progression Free Survival and Comparable Toxicity
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70136 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Renana Robinson und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological. Die Arbeit nennt 23 Literaturangaben. Gefördert von: NCATS NIH HHS, Stavros Niarchos Foundation, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Background
The GALLIUM trial showed improved progression‐free survival (PFS) with obinutuzumab (O)‐based chemoimmunotherapy in first‐line treatment of follicular lymphoma (FL), although with increased toxicity compared to rituximab (R). Our previous real‐world study found similar toxicity between these protocols during induction.
Aim
To compare real‐world toxicity and outcomes of R versus O maintenance therapy in FL patients following first‐line chemoimmunotherapy.
Methods
A multicenter retrospective study included FL patients treated with first‐line R‐ or O‐based chemoimmunotherapy. The primary outcome was any infection up to 6 months post‐maintenance. Secondary outcomes included other toxicities, PFS, and overall survival (OS).
Results
We analyzed 134 patients (R: 71, O: 63). Baseline characteristics were similar except for higher diabetes and hypertension rates in the R group. The median number of maintenance cycles was comparable. Infections occurred in 56% of patients, with no significant difference (50.7% R vs. 61.9% O, p = 0.21). Grade 3 infections, febrile neutropenia, and treatment discontinuation rates were comparable between groups. Pneumonia and viral infections were less frequent with R versus O (13.8% vs. 28.1%, p = 0.019 and 19% vs. 39%, p = 0.004, respectively), while infusion reactions were higher (8.4% vs. 0%, p = 0.028). After 5.5 years, PFS favored O (19.7% vs. 4.8%, p = 0.028), with similar OS.
Conclusions
In real‐world settings, rituximab‐ and obinutuzumab‐based chemoimmunotherapy with maintenance for FL exhibited a similar toxicity profile, with differences in specific infections. Obinutuzumab had superior PFS and similar OS compared with rituximab therapy, supporting obinutuzumab usage in first‐line chemoimmunotherapy, especially in selected young and fit patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.
- Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Laboratory of Genome Maintenance, The Rockefeller University, New York, New York, USA.
- Bio-Statistical Unit, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel.
- Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
ORCID-Profile: Renana Robinson, Reut Harel, Shai Shimony, Uri Abadi, Ronit Gurion
Förderung
- NCATS NIH HHS
- Stavros Niarchos Foundation
- National Center for Advancing Translational Sciences
Zitieren
APA
Robinson, R., Berger, T., Shochat, T., Aumann, S., Nachmias, B., Goldschmidt, N., Horesh, N., Harel, R., Aviv, A., Shimony, S., Goldberg, I., Shmerts, E., Abadi, U., Raanani, P., Gafter-Gvili, A., & Gurion, R. (2026). Obinutuzumab Maintenance in Follicular Lymphoma Is Associated With Better Progression Free Survival and Comparable Toxicity. European Journal of Haematology. https://doi.org/10.1111/ejh.70136
Vancouver
Robinson R, Berger T, Shochat T, Aumann S, Nachmias B, Goldschmidt N, et al. Obinutuzumab Maintenance in Follicular Lymphoma Is Associated With Better Progression Free Survival and Comparable Toxicity. European Journal of Haematology. 2026. doi:10.1111/ejh.70136
BibTeX
@article{Robinson2026,
author = {Robinson, Renana and Berger, Tamar and Shochat, Tzippy and Aumann, Shlomzion and Nachmias, Boaz and Goldschmidt, Neta and Horesh, Nurit and Harel, Reut and Aviv, Ariel and Shimony, Shai and Goldberg, Idan and Shmerts, Ella and Abadi, Uri and Raanani, Pia and Gafter-Gvili, Anat and Gurion, Ronit},
title = {Obinutuzumab Maintenance in Follicular Lymphoma Is Associated With Better Progression Free Survival and Comparable Toxicity},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70136}
}
EUVIMED